[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"heavy-menstrual-bleeding-hmb\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:heavy-menstrual-bleeding-hmb":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100643166","phase-2-hmbeacon-a-phase-2-study-to-evaluate-aln-6400-in-adult-and-adolescent-female-patients-with-vwd-and-hmb-100643166",false,"NCT07575308","HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB","HMBeacon: A Phase 2, Randomized, Double-blind Study of the Safety, Tolerability, Efficacy, and Pharmacodynamics of Multiple Dose ALN-6400 in Adult and Adolescent Female Patients With Von Willebrand Disease (VWD) and Heavy Menstrual Bleeding (HMB)","HMBeacon","Inclusion Criteria -\n\n* Is an adolescent or adult patient with a diagnosis of VWD (including Type 1, Type 2, Type 3, and platelet-type VWD) and HMB for 2 cycles during screening\n\nExclusion Criteria -\n\n* Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 2 times the upper limit of normal (ULN)\n* Has total bilirubin greater than 1.5×ULN (except for patients with Gilbert's syndrome)\n* Has an estimated glomerular filtration (eGFR) less than 30 mL\u002Fmin\u002F1.73m\\^2 at screening\n* Is not willing to comply with the contraceptive requirements during the study period\n* Used routine factor prophylaxis (greater than or equal to 1 infusion of factor per week over 12 weeks) within 4 weeks of screening or plans use for routine factor prophylaxis during the study\n* New placement of any hormonal or nonhormonal intrauterine device (IUD) or hormonal implants within 24 weeks of screening\n* Known current gynecological conditions causing abnormal uterine bleeding (including infection, fibroids, endometriosis, polycystic ovary syndrome, or dysplasia)\n\nNote: other protocol defined inclusion \u002F exclusion criteria apply","FEMALE","16 Years","45 Years",{"count":21,"type":22},24,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","The purpose of this study is to evaluate the safety, tolerability, efficacy, and pharmacodynamics (PD) of multiple doses of ALN-6400 in adult and adolescent patients with VWD and HMB",[28,29],"Von Willebrand Disease (VWD)","Heavy Menstrual Bleeding (HMB)",[31],"siRNA, RNAi therapeutic, Plasminogen, PLG, VWD, HMB","NOT_YET_RECRUITING","2026-06-11",{"date":35,"type":36},"2026-06-15","ACTUAL",{"date":38,"type":22},"2026-06-30",{"date":40,"type":22},"2028-11-29",{"name":42,"class":43},"Alnylam Pharmaceuticals","INDUSTRY"]